47 related articles for article (PubMed ID: 3264142)
1. Improved in vivo efficacy of tumor-infiltrating lymphocytes after restimulation with irradiated tumor cells in vitro.
Burger UL; Chang MP; Nagoshi M; Goedegebuure PS; Eberlein TJ
Ann Surg Oncol; 1996 Nov; 3(6):580-7. PubMed ID: 8915492
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Eberlein TJ; Rodrick ML; Massaro AF; Jung SE; Mannick JA; Schoof DD
Cancer Immunol Immunother; 1989; 30(3):145-50. PubMed ID: 2598183
[TBL] [Abstract][Full Text] [Related]
3. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.
Atzpodien J; Kirchner H
Klin Wochenschr; 1990 Jan; 68(1):1-11. PubMed ID: 2407894
[TBL] [Abstract][Full Text] [Related]
4. Aspergillus fumigatus contamination of lymphokine-activated killer cells infused into cancer patients.
Arnow PM; Houchins SG; Richards JM; Chudy R
J Clin Microbiol; 1991 May; 29(5):1038-41. PubMed ID: 2056038
[TBL] [Abstract][Full Text] [Related]
5. The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.
Baars JW; Hack CE; Wagstaff J; Eerenberg-Belmer AJ; Wolbink GJ; Thijs LG; Strack van Schijndel RJ; van der Vall HL; Pinedo HM
Br J Cancer; 1992 Jan; 65(1):96-101. PubMed ID: 1733448
[TBL] [Abstract][Full Text] [Related]
6. Metastatic renal cell cancer--is the outlook really improving?
Waxman J; Thomas H
Postgrad Med J; 1990 Jun; 66(776):435-40. PubMed ID: 1699216
[No Abstract] [Full Text] [Related]
7. [LAK cells and cancer].
Taguchi T; Kimoto Y
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3327-33. PubMed ID: 3539024
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells.
Rosenberg SA
Important Adv Oncol; 1988; ():217-57. PubMed ID: 3042605
[No Abstract] [Full Text] [Related]
9. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
[TBL] [Abstract][Full Text] [Related]
10. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
Rosenberg SA; Lotze MT; Muul LM; Chang AE; Avis FP; Leitman S; Linehan WM; Robertson CN; Lee RE; Rubin JT
N Engl J Med; 1987 Apr; 316(15):889-97. PubMed ID: 3493432
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
13. [A new approach in the treatment of metastatic melanoma: adoptive immunotherapy using lymphokine-activated killer cells and interleukin 2].
Keilholz U; Welters H; Dummer R; Tilgen W; Hunstein W
Hautarzt; 1988 Jun; 39(6):378-81. PubMed ID: 3261288
[TBL] [Abstract][Full Text] [Related]
14. A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicity.
Eberlein TJ; Schoof DD; Jung SE; Davidson D; Gramolini B; McGrath K; Massaro A; Wilson RE
Arch Intern Med; 1988 Dec; 148(12):2571-6. PubMed ID: 3264142
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
